Yo tuve mi época de metesacas cortoplacistas de minutos/horas ... Fueron unos años intensos, salieron bien pero muchas horas pegado a la pantalla. En realidad dos pantallas repletas de señales. Me harté/agoté/quemé.
framus_morrigan06/11/26 21:56
Ha respondido al tema
Pulso de Mercado: Intradía
Menudo Jueves, pedazo Viernes ...Están locos estos romanos...
framus_morrigan06/11/26 16:28
Ha respondido al tema
Pulso de Mercado: Intradía
Menuda semana loca que llevamos 🤪
framus_morrigan06/11/26 08:57
Ha respondido al tema
Pulso de Mercado: Intradía
ETF nuclear NUKLMayor nivel de sobreventa en diarioRSI en 25,7
framus_morrigan05/11/26 23:00
Ha respondido al tema
Pulso de Mercado: Intradía
Hace 4 o 5 años un día como hoy (+ lo ya bajado los ultimos 2 meses), me tendría desquiciado. Tiempos pasados que sé que ya no volverán... Cabeza fría, una estrategia, paciencia, pico y pala.
framus_morrigan05/11/26 20:32
Ha respondido al tema
Pulso de Mercado: Intradía
VIXun gap de apertura mañana en zona 35 y empiezo a promierdiar en alguna ...
jodido en todos los frentes mas allá de toda recuperación este año, al menos. hacia tiempo ... tenia que llegar algún día ...
framus_morrigan05/11/26 15:07
Ha respondido al tema
Otras Aventuras de los Farmas USA
sector DATA CENTERSmensualesvistazo rapido, no me interesan por ahora porque guardo el cash para promediar mi otras batallasCIFR CRWV IREN NBIS
framus_morrigan05/11/26 14:07
Ha respondido al tema
Novavax (NVAX): Un Nuevo Comienzo
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approvalDifferentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027Multiple Novavax and partner-led experiments with Matrix-M® currently underway in a wide array of infectious disease targets and oncology modelsCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Nov. 5, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2026."This quarter, we continued to execute across all three pillars of our strategy," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health."Third Quarter 2026 and Recent HighlightsKey Business Highlights In October 2026, Novavax earned a $125 million milestone payment with the initiation of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial in EuropeSanofi confirmed to Novavax their intent to initiate a U.S. Phase 3 CIC trial in 2027 to support U.S. approval. Novavax is eligible to receive an additional milestone of $225 million upon a U.S. commercial launch of a CIC vaccine following successful completion by Sanofi of clinical and U.S. FDA regulatory requirements.Novavax is eligible to receive royalties in the high single digits to sub-teens as a percentage of Sanofi's global net sales on a CIC product(s).Manufacturing technology transfer to Sanofi for Nuvaxovid™ is expected to be completed in mid-2027, which would trigger a $75 million milestone payment to Novavax.In August 2026, Novavax's commercial partners received approvals for the XFG-adapted Nuvaxovid formulation in major markets, including the U.S., the EU and Japan.Sanofi initiated commercial activities for the 2026–2027 COVID-19 vaccination season in the U.S. and select international markets.Sanofi is expanding Nuvaxovid's reach through physician engagement, pharmacy activation and direct-to-consumer outreach.Novavax is eligible to receive royalties in the high teens to low twenties as a percentage of Sanofi's global net sales for Nuvaxovid.Takeda initiated commercial activities for the 2026–2027 COVID-19 vaccination season in Japan.Novavax is eligible to receive an annual milestone payment and mid-to-high teens percentage of Takeda's net sales in Japan each year.Differentiated C. difficile (C. diff) vaccine program is anticipated to advance into the clinic as early as 2027.Novavax presented preclinical data from its C. diff program showing robust immune responses and protection in lethal challenge models at the 9th International C. Difficile Symposium in September 2026.Multiple scientific evaluations by Novavax, partners and material transfer agreement collaborations are underway. These are expected to add to the growing body of data relating to Matrix-M's utility in infectious disease and its potential in oncology, which could enable future licensing opportunities.